ロード中...
HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
Although multiple myeloma (MM) patients benefit from standard bortezomib (BTZ) chemotherapy, they develop drug resistance, resulting in relapse. We investigated whether histone deacetylase 6 (HDAC6) inhibitor A452 overcomes bortezomib resistance in MM. We show that HDAC6-selective inhibitor A452 sig...
保存先:
| 出版年: | Int J Mol Sci |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7866276/ https://ncbi.nlm.nih.gov/pubmed/33572814 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms22031341 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|